摘要
目的观察复方苦参注射液联合贝伐珠单抗注射液治疗晚期结直肠癌的临床疗效。方法63例晚期结直肠癌患者,采用随机抽签方式分为对照组(30例)与观察组(33例)。两组均给予FOLFIRI方案化疗,对照组给予贝伐珠单抗注射液治疗,观察组给予复方苦参注射液联合贝伐珠单抗注射液治疗。比较两组的临床疗效、免疫功能指标、肿瘤标志物水平。结果观察组客观缓解率48.48%高于对照组的23.33%(P<0.05)。治疗后,两组CD4^(+)、CD4^(+)/CD8^(+)高于本组治疗前,CD8^(+)低于本组治疗前,且观察组CD4^(+)(37.54±3.71)%、CD4^(+)/CD8^(+)(1.33±0.11)高于对照组的(31.29±3.95)%、(1.04±0.08),CD8^(+)(27.49±4.86)%低于对照组的(30.22±4.31)%(P<0.05)。治疗后,两组血清糖蛋白抗原-199、癌胚抗原水平均低于本组治疗前,且观察组糖蛋白抗原-199(21.63±5.18)U/ml、癌胚抗原(12.08±3.12)μg/L低于对照组的(26.48±6.03)U/ml、(16.43±3.76)μg/L(P<0.05)。结论复方苦参注射液联合贝伐珠单抗注射液治疗晚期结直肠癌能够提高患者的客观缓解率,改善其免疫功能,降低肿瘤标志物水平,提高预后质量。
Objective To observe the clinical efficacy of compound sophora flavescens injection combined with bevacizumab injection in the treatment of advanced colorectal cancer.Methods 63 patients with advanced colorectal cancer were divided into control group(30 cases)and observation group(33 cases)by random lottery method.Both groups were given FOLFIRI chemotherapy.On this basis,the control group was given bevacizumab injection,and the observation group was given compound sophora flavescens injection combined with bevacizumab injection.The clinical efficacy,immune function indexes and tumor marker level of the two groups were compared.Results The objective remission rate of 48.48%in the observation group was higher than 23.33%in the control group(P<0.05).After treatment,CD4^(+)and CD4^(+)/CD8^(+)in both groups were higher than those before treatment,and CD8^(+)was lower than that before treatment;the observation group had CD4^(+)of(37.54±3.71)%and CD4^(+)/CD8^(+)of(1.33±0.11),which were higher than(31.29±3.95)%and(1.04±0.08)in the control group;the observation group had a lower CD8^(+)of(27.49±4.86)%than(30.22±4.31)%in the control group(P<0.05).After treatment,the levels of serum carbohydrate antigen 199 and carcinoembryonic antigen in both groups were lower than those before treatment;the levels of serum carbohydrate antigen 199 and carcinoembryonic antigen were glycoprotein antigen-199(21.63±5.18)U/ml and(12.08±3.12)μg/L in the observation group,which were lower than(26.48±6.03)U/ml and(16.43±3.76)μg/L in the control group(P<0.05).Conclusion The combination of compound sophora flavescens injection can improve the objective remission rate,improve the immune function,lower levels of tumor markers and improve the prognosis of patients with advanced colorectal cancer.
作者
赵宁
ZHAO Ning(Binzhou Central Hospital,Binzhou 251700,China)
出处
《中国实用医药》
2025年第10期137-140,共4页
China Practical Medicine
关键词
复方苦参注射液
贝伐珠单抗注射液
晚期结直肠癌
效果
Compound sophora flavescens injection
Bevacizumab injection
Advanced colorectal cancer
Effect
